Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Craig S. Owens who wrote (667)	9/3/1999 4:49:00 PM
From: Dr. John M. de Castro	Read Replies (2) of 1494

Craig, the abstract says that a class of drugs, the NMDA antagonists, have great potential for protecting the nervous system from damage in a wide variety of circumstances. The problem has been that most of the NMDA antagonists that have been developed have nasty side effects. This has led to the notion that NMDA antagonists are not good candidates for neuroprotection. However, memantine is different. It is effective and at the doses that have clinically useful effects, there are only very mild side effects. Hence, memantine, unlike other NMDA antagonists, is safe and effective. So, all of that great potential for NMDA antagonists can be realized with memantine. I hope that helps. I don't post the abstracts to confuse people. I just like to put the data out there raw and unedited so there is no hyping involved, only the facts. Best regards for a great holiday weekend John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next